Preliminary results of the Phase Ib/II trials in TP53-mutated myelodysplastic syndrome in combination with azacitidine showed 74% overall response rate (ORR) and 59% complete remission (CR) rate in 27 evaluable MDS patients (https://clinicaltrials.gov/show/NCT03588078). Here, TP53 is linked to myelodysplastic syndrome.